Objective: Washington State mandated seven hospital "best practices" in July 2012, several of which may affect emergency department (ED) opioid prescribing and provide a policy template for addressing the opioid prescription epidemic. We tested the hypothesis that the mandates would reduce opioid dispensing after an ED visit. We further assessed for a selective effect in patients with prior risky or chronic opioid use.
D
rug overdoses have exceeded motor vehicle collisions as the leading cause of accidental mortality, and this epidemic has been fueled by prescription opioid abuse. 1 The 16,000 prescription opioid-related overdose deaths reported in 2012 reflect a threefold increase since 1999 and far surpass deaths from heroin. 2 Emergency departments (EDs) represent particularly high-risk settings for doctor shopping and drug diversion [3] [4] [5] [6] Individuals predisposed toward the misuse or diversion of opioids may frequently seek prescriptions from EDs. 6, 7 Contributing factors include the episodic nature of emergency care, lack of a long-term physician-patient relationship, and the absence of coordinated data systems to track ED or doctor shopping behaviors. A variety of policy solutions have been suggested, 8 although to date there has been scant evidence of effectiveness.
Washington State mandated seven hospital "best practices" to reduce potentially avoidable ED visits by Medicaid beneficiaries. 9, 10 Several of these mandates may directly or indirectly affect ED opioid prescribing, including adoption of an ED information exchange (EDIE) system to track visits to multiple EDs (which may be an indicator of "doctor shopping"), identification of frequent ED visitors including those with opioid seeking behavior, implementation of opioid prescribing guidelines, 11 and enrollment of ED providers in the state's prescription monitoring program (PMP).
Importance
Evidence of effectiveness may provide a policy template for other states to selectively reduce ED opioid prescribing to patients at high risk of overdose. Assessing the effect of these mandates is particularly important for Medicaid beneficiaries, who have a 10-fold higher rate of fatal prescription opioid overdose compared to privately insured populations. 12 
Goal of This Investigation
We assessed the impact of the Washington State hospital mandates on prescription opioid dispensing after an ED visit for Medicaid patients. We hypothesized that the mandates would be associated with reduced post-visit opioid dispensing. We further assessed for a selective effect for patients with prior risky opioid use behavior (e.g., suggestive of doctor or pharmacy shopping) or a history of chronic opioid use, as such patients were likely to be differentially affected by the mandates.
METHODS

Study Design
We performed a retrospective cohort study of ED visits by Washington State Medicaid beneficiaries. To evaluate the longitudinal effects of the hospital mandates intervention, we used a quasi-experimental study design known as an interrupted time series analysis. This study design is a powerful statistical method increasingly used for the evaluation of public health interventions. A strength of the interrupted times series design is that it controls for underlying temporal trends. Rather than comparing different groups of patients at a single point in time, researchers follow patient groups over time, to assess whether a change in policy is accompanied by a change in health. 13, 14 The Washington State Health Care Authority provided Medicaid beneficiary level medical and pharmacy claims data. The Institutional Review Boards of Washington State and of Oregon Health and Science University approved this study.
Cohort Selection and Rationale
We studied Medicaid beneficiaries in Washington State from July 1, 2011, to June 30, 2013 . This allowed analysis of opioid prescribing in the 12 months before and after the hospital mandates. This time frame excludes Medicaid eligibility expansion under the Affordable Care Act, which began in January 2014 in Washington State. We excluded observations for members with a history of active cancer in the prior year, as opioid treatment is accepted for cancer pain. 15 We excluded beneficiaries who were dually eligible for Medicare and Medicaid due to incomplete claims. Children under 15 years of age were excluded. We excluded observations for members who were enrolled for less than 3 months during the prior year to have sufficient data on preexisting comorbidities. Finally, we excluded patients who received hospice or nursing home care at any time during the study period, since opioid analgesics are a widely accepted treatment for hospice patients, 15 and institutional providers are likely responsible for medication management in nursing facilities.
We included ED visits by qualifying Medicaid beneficiaries during the study period. ED visits that required observation services or resulted in hospital admission were excluded. We excluded Medicaid managed care visits from the analysis, as pharmacy claims reporting was unreliable for managed care beneficiaries during the study period. Thus, only Medicaid fee-forservice (FFS) visits were included in the analysis.
Outcomes
The primary outcome was any prescription opioid dispensing within 3 days following an ED visit, defined as a paid pharmacy claim for any Schedule II opioid, including codeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, oxycodone, oxymorphone, and tapentadol.
We also measured the total morphine milligram equivalents (MMEs) dispensed within 3 days following an ED or PCP encounter. We used the following conversion factors to calculate MMEs: [16] [17] [18] codeine, 0.15; fentanyl citrate, 0.13; fentanyl patch, 7.2; hydrocodone, 1; hydromorphone, 4; levorphanol, 11; meperidine, 0.1; methadone, 3; morphine, 1; oxycodone, 1.5; oxymorphone, 3; and tapentadol, 0.4.
Intervention: Description of Mandates 10
Third Engrossed Substitute House Bill 2127 set forth best practices aimed at reducing potentially unnecessary ED use by Medicaid clients. All Washington hospitals with EDs serving Medicaid clients attested to their agreement to these practices on or before July 1, 2012. These best practices include: 1. Adoption of a system to exchange patient information electronically among EDs. The electronic information system allows ED physicians to see all of the patient's emergency room visits from all hospitals over the past 12 months and to know the diagnosis and treatment given on these previous visits. 2. Adoption of a system to educate patients that the ED should be used only for true emergencies. Every hospital has now agreed to provide patients with a brochure and/or discharge instructions discussing the most appropriate setting for their health care. Hospitals have also attested that they have trained ED physicians in how to talk to patients about where they should receive care for nonemergent needs. 3. Implementation of a process to disseminate lists of frequent users to hospital personnel to ensure that they can be identified by the electronic information exchange system discussed above. 4. Implementation of processes to assist frequent users with their care plans and to make appointments for these patients to see their primary care provider within 72-96 hours of their emergency room visit. 5. Adoption of strict guidelines for the prescribing of narcotics. Hospitals have also attested that they have trained ED physicians in how to enforce these guidelines. 6 . Enrollment of at least 75% of ED prescribers in the state's PMP by July 1, with a goal of 90% enrollment by December 31, 2012. The PMP is an electronic online database used to collect data on patients who are prescribed controlled substances. It enables prescribers to see which prescriptions have been previously filled by a patient. This is essential information to reduce the number of patients seeking narcotics. 7. Designation of hospital personnel to review feedback reports regarding ED utilization and to take appropriate action in response to the information provided by those reports.
Measures
We included an expansive set of patient-level case-mix measures, evaluated during each calendar quarter. These were identified by literature review or determined by the study team to be potential predictors of opioids use. Demographics included age, sex, race, and Hispanic ethnicity. We also include an indicator of disability status based on Medicaid eligibility records. The presence of 17 physical health condition categories was evaluated using the Chronic Illness and Disability Payment System, which has been validated for use in Medicaid populations. 19 Specific mental health and substance abuse diagnoses were identified through medical claims using the previously described Ettner classification system. 20 We assessed whether any of the diagnoses associated with ED visits were related to painful symptoms or conditions (Data Supplement S1, eTable 1, available as supporting information in the online version of this paper, which is available at https://doi.org/onlinelibrary.wiley.com/d oi/10.1111/acem.13230/full). 21, 22 For the subgroup analyses, we compiled data on history of opioid and benzodiazepine use and number of prescribers and pharmacies in the 6 months prior to the visit. We created an indicator for chronic opioid use, defined as ≥120 days of opioid supply in the prior 6 months. 23 We also created an indicator for history of prior risky opioid use behaviors (i.e., suggestive of diversion or associated with increased overdose risk) in the past 6 months, 15, 24, 25 including ≥90 dispensed MMEs/day, five or more prescribers, five or more dispensing pharmacies, or any instance of overlapping opioid and benzodiazepine prescriptions for more than 1 week.
Data Analysis: Interrupted Time Series
The implementation of time interrupted time-series analysis required that visit-level data be aggregated to ACADEMIC EMERGENCY MEDICINE • August 2017, Vol. 24, No. 8 • www.aemj.org the month level, with 12 data points in each of the pre-and postintervention periods. We ran 24 multivariate logistic regression models with visit-level data, one for each month, and obtained the adjusted opioid dispensed outcome at the visit level of analysis. Similarly, we ran 24 multivariate linear regression models to obtain the adjusted MMEs, after restricting to visits associated with any dispensed MME. 26 Within each month, we adjusted the outcomes by patient demographics, history of physical and mental health disorders, and presence of a pain-related diagnosis. 27 Minimum sample size criteria of at least 100 observations within each month was met. The mean adjusted outcomes were calculated by aggregating adjusted outcomes at visit level to the month level. Data are reported as mean AE SD or n (%). *Indicates whether a beneficiary qualified for Medicaid based on disability status. †History of physical health conditions indicates whether the enrollee had a 1-year history of the condition of interest at the time when the visit occurred. Health condition categories were constructed using the Chronic Illness and Disability Payment System (CDPS). ‡History of behavioral health conditions indicates whether the enrollee had a 1-year history of the condition of interest at the time when the visit occurred. Condition categories were constructed using Ettner classifications. Behavioral health conditions are underestimated since mental health claims are not included in the data. §Including bipolar disorder, dysthmia or other depressive disorder, and major depression. ||Including schizophrenia and other nonmood disorders, adjustment disorders, disorders originating in childhood (e.g., infantile autism), anxiety disorders, other behavioral conditions, and personality disorders. ¶Including sickle cell with crisis, acute pancreatitis, pathologic fracture, acute pain not otherwise specified, and pain related to HIV/AIDS
The interrupted time-series models were of the for:
here, Y t is the mean adjusted outcome in month t; Month t indicates the time in months from July 2011, the first month of the study; Intervention t is the dummy-level change indicator for time occurring before or after the hospital mandates; and PostMonth t is the slope variable counting the number of months after intervention(Month t -12). We estimated changes in level and trend by using general linearized models with a logit link function (for the primary binary outcome of any dispensed opioid) or ordinary least square models (for the secondary continuous outcome of dispensed MMEs). Basic assumptions for modeling the data were met, including detection of outliers and influential data points, multicollinearity, and assumption of linearity in the logit for continuous covariates.
To improve interpretability, we presented results as marginal effects of explanatory variables using recycled predictions (i.e., average of the probabilities). 28 For example, to obtain a marginal effect of the postmandate period indicator, we first computed the predicted probability of outcome for each data time point, assuming that the visit occurred in the premandate period, and averaged those predicted probabilities. We then calculated the predicted probabilities, assuming that the visit occurred in the postmandate period, and averaged them again. The change in the mean predicted probabilities is the marginal effect of the postmandate period indicator.
We also examined two subgroups: patients with prior risky opioid use and patients with chronic opioid use. All analyses described above were repeated for these two specific subgroups. We analyzed all available data and did not perform a priori power calculations. All data management and statistical analyses were performed in R version 3.2.2 29 and STATA MP 14.0. Table 2 describes unadjusted pre-and postmandate rates of outcomes. Figure 1 illustrates unadjusted outcomes over time, for the overall cohort as well as for the predefined subgroups. Table 2 and Figure 1 suggest a trend toward reduced ED dispensing over time but not for quantity of MMEs per prescription.
RESULTS
Adjusted outcomes are presented in Table 3 . The mean number of opioid dispensed prescriptions per visit per month after an ED visit declined in the overall cohort (-1.5%, 95% confidence interval [CI] = -2.8% to -0.2%) in the postmandate period, with no change in underlying temporal trends. There was no change in the MMEs associated with dispensed opioids (-15.4, 95% CI = -32.5 to 1.7).
For visits by patients with prior risky opioid use behavior (n = 42,494), the mandates were associated with decreased opioid dispensing after an ED visit (-4.7%, 95% CI = -7.1% to -2.3%) but not for MMEs dispensed (29.1, 95% CI = -98.5 to 38.3). For visits by patients with chronic opioid use (n = 20,238), the mandates were associated with decreased opioid dispensing after an ED visit (-3.6%, 95% CI = -5.6% to -1.7%) but not for MMEs dispensed (-81.1, 95% CI = -203.4 to 41.2). The 95% CIs for impact on the primary outcome overlapped between the overall cohort and two subgroups. Mandates were not associated with changes in the temporal trajectories (i.e., slopes) for any of the outcomes.
DISCUSSION
In this statewide, quasi-interventional study of Medicaid FFS beneficiaries, we found that hospital best practice mandates were associated with small reductions in opioid dispensing after an ED visit. There did not appear to be a selective effect on patients with prior risky or chronic opioid use, and the quantity of opioids per dispense did not change. We did note an underlying trend toward less prescription opioid dispensing over time that was unrelated to the mandates. Our results suggest that the Washington State mandates are a relatively weak policy lever to reduce ED opioid prescribing. The bundled mandates suggest several potential mechanisms for the small observed effect. The statewide EDIE system "pushes" data about all ED visits by a unique patient in the prior year in nearly real time electronically or by fax, if the patient has had more than five ED visits in the prior 12 months (facilities can modify this trigger to more than five ED visits in the prior 6 months). EDIE allows providers to identify patients who may be seeking care at multiple EDs for similar complaints, including symptoms related to pain. Care management plans for frequent ED visitors, including pain management contracts, can be embedded within the EDIE report. The Washington State ED opioid guidelines were developed and endorsed by a multiple specialty group, and they specifically advocate for judicious ED administration and prescription of opioids for patients with chronic pain. 30 Finally, ED providers were required to register for the state PMP, which is a database that tracks all dispensed controlled substances to unique patients. 31 Information in the PMP may help providers identify high-risk patients, such as those with multiple opioid prescribers and/or dispensers, overlapping opioid prescriptions, and overlapping opioid and benzodiazepine prescriptions.
We did not find evidence of a selective effect in risky and chronic users of prescription opioids, and opioid dispensing after an ED visit remains substantial in these subgroups. The overall prescription rates in these groups exceeded 25% (greater than the 19% rate reported from a nationally representative sample of all ED visits 32 ). We suggest potential explanations for the small and nonselective impact of the mandates, as well as possible solutions. First, although EDIE data are pushed to hospitals, it is unknown how often ED providers review and act upon such information. Provider education may improve use of EDIE information. Second, it is possible that patients who could have benefited from care management plans did not have one available in EDIE. Continued identification of frequent ED visitors and entry of care plans may reduce inappropriate opioid prescribing. Finally, PMP data may alter prescribing behavior, 33, 34 but only a small fraction of physicians use the PMP. 35 Multiple logistic barriers have been identified, including Web pages that are difficult to navigate, frequent requirements for password updates, and time needed to access clinically useful information. 36, 37 Furthermore, providers may be uncertain about how to interpret and act upon PMP data. Some data suggest that mandated queries may be more effective than voluntary use. 38 Washington state has recently integrated an automated PMP query into the EDIE system, and future evaluation studies will assess whether "pushed" PMP data impacts provider practices. In addition, decision support systems that distill PMP data into actionable recommendations may facilitate clinical care.
LIMITATIONS
First, our analysis was limited to ED visits by Medicaid FFS beneficiaries (representing~30% of all beneficiaries during the study period). We chose to study the Medicaid population because Medicaid beneficiaries are at elevated risk of prescription opioid overdose and were the specific targets of the hospital mandates. We focused on Medicaid FFS encounters, as Washington State managed care pharmacy data were unreliable during the study period. The FFS population had high rates of disability and prior substance use disorders, and it is likely that the mandates would have had even weaker effects in healthier managed care beneficiaries. Further work is required to verify our findings in other populations.
Second, there may have been measurement error associated with our use of pharmacy claims data. Claims data would miss cash payments for prescription opioids, and "criterion standard" PMP dispense data linked at the beneficiary level were not uniformly available during the study time period. Prescriber identifying information was also frequently missing in pharmacy claims, and it is possible that some 3-day opioid prescriptions were misattributed to the index ED visit. These potential [39] [40] [41] [42] [43] Our definition of five or more prescribers, or five or more dispensers, is based on suggested thresholds from the Substance Abuse and Mental Health Services Administration. 24 It is possible that our findings may be sensitive to other definitions.
Fourth, our study focused on Schedule II prescription opioids, which have the highest potential for abuse. The impact of best practice mandates of Schedule III prescription opioids was not explored and should be assessed in future studies.
Fifth, we cannot directly assess the appropriateness of opioid dispensing through claims data. However, we believe that opioids should be judiciously prescribed to patients with prior high-risk behaviors or who have chronic pain managed by other providers.
Finally, although our analyses attempted to control for patient factors and temporal trends, there will always be the possibility of unmeasured confounding in observational data.
CONCLUSIONS
In summary, we found that Washington State hospital best practice mandates were associated with small reductions in prescription opioid dispensing after an ED visit. There was no evidence of a selective effect on patients with prior risky or chronic opioid use. States should focus on alternative policies to reduce opioid dispensing to targeted subgroups.
